Publications

Found 1 results
Filters: Author is S.R. Lin  [Clear All Filters]
2011
M. Y. Huang, Chen, M. J., Tsai, H. L., Kuo, C. H., Ma, C. J., Hou, M. F., Chuang, S. C., Lin, S. R., and Wang, J. Y., Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens, vol. 10, pp. 3002-3012, 2011.
Arnold D, Hohler T, Dittrich C, Lordick F, et al. (2008). Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann. Oncol. 19: 1442-1449. http://dx.doi.org/10.1093/annonc/mdn150 PMid:18441330 Bleiberg H (1996). Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol. 23: 42-50. Cunningham D, Humblet Y, Siena S, Khayat D, et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351: 337-345. http://dx.doi.org/10.1056/NEJMoa033025 PMid:15269313 Department of Health, Executive Yuan (2007). Statistics on Leading Causes of Cancer Death. Bureau of National Health Insurance, Taiwan. Fakih M (2008). The role of targeted therapy in the treatment of advanced colorectal cancer. Curr. Treat. Options Oncol. 9: 357-374. http://dx.doi.org/10.1007/s11864-009-0089-1 PMid:19238551 Fang JY and Richardson BC (2005). The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 6: 322-327. http://dx.doi.org/10.1016/S1470-2045(05)70168-6 Folprecht G, Lutz MP, Schoffski P, Seufferlein T, et al. (2006). Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann. Oncol. 17: 450-456. http://dx.doi.org/10.1093/annonc/mdj084 PMid:16303861 Giacchetti S, Perpoint B, Zidani R, Le Bail N, et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18: 136-147. PMid:10623704 Giovanella BC, Stehlin JS, Wall ME, Wani MC, et al. (1989). DNA topoisomerase I - targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048. http://dx.doi.org/10.1126/science.2555920 PMid:2555920 Hemming AW, Davis NL, Kluftinger A, Robinson B, et al. (1992). Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J. Surg. Oncol. 51: 147-152. http://dx.doi.org/10.1002/jso.2930510304 PMid:1434639 Kallen KJ, Hofmann MA, Timm A, Godderz W, et al. (2000). Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. Z. Gastroenterol. 38: 153-157. http://dx.doi.org/10.1055/s-2000-14853 PMid:10721170 Lenz HJ, Van Cutsen E, Khambata-Ford S, Mayer RJ, et al. (2006). Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 24: 4914-4921. http://dx.doi.org/10.1200/JCO.2006.06.7595 PMid:17050875 Lievre A, Bachet JB, Boige V, Cayre A, et al. (2008). KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26: 374-379. http://dx.doi.org/10.1200/JCO.2007.12.5906 PMid:18202412 Liu LF, Desai SD, Li TK, Mao Y, et al. (2000). Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 922: 1-10. http://dx.doi.org/10.1111/j.1749-6632.2000.tb07020.x PMid:17132771 Loe DW, Deeley RG and Cole SP (1996). Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer 32A: 945-957. http://dx.doi.org/10.1016/0959-8049(96)00046-9 Maindrault-Goebel F, de Gramont A, Louvet C, Andre T, et al. (2001). High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur. J. Cancer 37: 1000-1005. http://dx.doi.org/10.1016/S0959-8049(01)00068-5 Martin-Martorell P, Rosello S, Rodriguez-Braun E, Chirivella I, et al. (2008). Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br. J. Cancer 99: 455-458. http://dx.doi.org/10.1038/sj.bjc.6604530 PMid:18665167    PMCid:2527794 Midgley RS, Yanagisawa Y and Kerr DJ (2009). Evolution of nonsurgical therapy for colorectal cancer. Nat. Clin. Pract. Gastroenterol. Hepatol. 6: 108-120. http://dx.doi.org/10.1038/ncpgasthep1337 Min BS, Kim NK, Ahn JB, Roh JK et al. (2007). Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. Onkologie 30: 637-643. http://dx.doi.org/10.1159/000109957 PMid:18063876 Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108. http://dx.doi.org/10.3322/canjclin.55.2.74 Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, et al. (2007). Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol. 46: 697-701. http://dx.doi.org/10.1080/02841860601009455 PMid:17562448 Recchia F, Candeloro G, Necozione S, Bratta M, et al. (2008). Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. 31: 323-328. http://dx.doi.org/10.1097/COC.0b013e318163736e PMid:18845989 Reidy D and Saltz L (2007). Targeted strategies in the treatment of metastatic colon cancer. J. Natl. Compr. Canc. Netw. 5: 983-990. PMid:17977504 Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, et al. (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22: 1201-1208. http://dx.doi.org/10.1200/JCO.2004.10.182 PMid:14993230 Sambrook J, Jritsch E and Maniatis T (1989). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory, New York. Tabernero J, Van Cutsem E, Diaz-Rubio E, Cervantes A, et al. (2007). Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25: 5225-5232. http://dx.doi.org/10.1200/JCO.2007.13.2183 PMid:18024868 Teufel A, Steinmann S, Siebler J, Zanke C, et al. (2004). Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 4: 38. http://dx.doi.org/10.1186/1471-2407-4-38 PMid:15265233    PMCid:497044 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216. http://dx.doi.org/10.1093/jnci/92.3.205 PMid:10655437 van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, et al. (1998). Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br. J. Cancer 77: 2171-2176. http://dx.doi.org/10.1038/bjc.1998.362 PMid:9649129    PMCid:2150393 Van Cutsem E, Kohne CH, Hitre E, Zaluski J, et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360: 1408-1417. http://dx.doi.org/10.1056/NEJMoa0805019 PMid:19339720 Wang JY, Hsieh JS, Chen FM, Yeh CS, et al. (2003). High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. Int. J. Cancer 107: 387-393. http://dx.doi.org/10.1002/ijc.11417 PMid:14506738 Yen LC, Uen YH, Wu DC, Lu CY, et al. (2010). Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann. Surg. 251: 254-260. http://dx.doi.org/10.1097/SLA.0b013e3181bc9d96 PMid:20010090